241 related articles for article (PubMed ID: 37310268)
21. Bedaquiline: a novel antitubercular agent for the treatment of multidrug-resistant tuberculosis.
Worley MV; Estrada SJ
Pharmacotherapy; 2014 Nov; 34(11):1187-97. PubMed ID: 25203970
[TBL] [Abstract][Full Text] [Related]
22. Twenty-four-week interim outcomes of bedaquiline-containing regimens in treatment of adolescents with rifampicin-resistant tuberculosis: A retrospective cohort study in China.
Wu HY; Tian Y; Wang XD; Sun JS; Fan LC; Chen MX; Li R; Chen Y
J Paediatr Child Health; 2022 Jan; 58(1):116-121. PubMed ID: 34323328
[TBL] [Abstract][Full Text] [Related]
23. Impact of Prior Tuberculosis Treatment With New/Companion Drugs on Clinical Outcomes in Patients Receiving Concomitant Bedaquiline and Delamanid for Multidrug- and Rifampicin-Resistant Tuberculosis.
Mikiashvili L; Kempker RR; Chakhaia TS; Bablishvili N; Avaliani Z; Lomtadze N; Schechter MC; Kipiani M
Clin Infect Dis; 2024 Apr; 78(4):1043-1052. PubMed ID: 37962987
[TBL] [Abstract][Full Text] [Related]
24. Bedaquiline: a novel diarylquinoline for multidrug-resistant tuberculosis.
Chahine EB; Karaoui LR; Mansour H
Ann Pharmacother; 2014 Jan; 48(1):107-15. PubMed ID: 24259600
[TBL] [Abstract][Full Text] [Related]
25. Primary Clofazimine and Bedaquiline Resistance among Isolates from Patients with Multidrug-Resistant Tuberculosis.
Xu J; Wang B; Hu M; Huo F; Guo S; Jing W; Nuermberger E; Lu Y
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28320727
[TBL] [Abstract][Full Text] [Related]
26. First report of whole-genome analysis of an extensively drug-resistant Mycobacterium tuberculosis clinical isolate with bedaquiline, linezolid and clofazimine resistance from Uganda.
Kabahita JM; Kabugo J; Kakooza F; Adam I; Guido O; Byabajungu H; Namutebi J; Namaganda MM; Lutaaya P; Otim J; Kakembo FE; Kanyerezi S; Nabisubi P; Sserwadda I; Kasule GW; Nakato H; Musisi K; Oola D; Joloba ML; Mboowa G
Antimicrob Resist Infect Control; 2022 May; 11(1):68. PubMed ID: 35550202
[TBL] [Abstract][Full Text] [Related]
27. World Health Organization 2018 treatment guidelines for rifampicin-resistant tuberculosis: uncertainty, potential risks and the way forward.
Van Deun A; Decroo T; Tahseen S; Trébucq A; Schwoebel V; Ortuno-Gutierrez N; de Jong BC; Rieder HL; Piubello A; Chiang CY
Int J Antimicrob Agents; 2020 Jan; 55(1):105822. PubMed ID: 31626907
[TBL] [Abstract][Full Text] [Related]
28. Early outcome and safety of bedaquiline-containing regimens for treatment of MDR- and XDR-TB in China: a multicentre study.
Gao M; Gao J; Xie L; Wu G; Chen W; Chen Y; Pei Y; Li G; Liu Y; Shu W; Fan L; Wu Q; Du J; Chen X; Tang P; Xiong Y; Li M; Cai Q; Jin L; Mei Z; Pang Y; Li L
Clin Microbiol Infect; 2021 Apr; 27(4):597-602. PubMed ID: 32553880
[TBL] [Abstract][Full Text] [Related]
29. A safety evaluation of bedaquiline for the treatment of multi-drug resistant tuberculosis.
Cohen K; Maartens G
Expert Opin Drug Saf; 2019 Oct; 18(10):875-882. PubMed ID: 31339384
[No Abstract] [Full Text] [Related]
30. QT Interval Prolongation in People Treated With Bedaquiline for Drug-Resistant Tuberculosis Under Programmatic Conditions: A Retrospective Cohort Study.
Isralls S; Baisley K; Ngam E; Grant AD; Millard J
Open Forum Infect Dis; 2021 Aug; 8(8):ofab413. PubMed ID: 34466629
[TBL] [Abstract][Full Text] [Related]
31. Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study.
Ismail NA; Omar SV; Moultrie H; Bhyat Z; Conradie F; Enwerem M; Ferreira H; Hughes J; Joseph L; Kock Y; Letsaolo V; Maartens G; Meintjes G; Ngcamu D; Okozi N; Padanilam X; Reuter A; Romero R; Schaaf S; Te Riele J; Variava E; van der Meulen M; Ismail F; Ndjeka N
Lancet Infect Dis; 2022 Apr; 22(4):496-506. PubMed ID: 34780706
[TBL] [Abstract][Full Text] [Related]
32. Effects on the QT Interval of a Gatifloxacin-Containing Regimen versus Standard Treatment of Pulmonary Tuberculosis.
Olliaro PL; Merle C; Mthiyane T; Bah B; Kassa F; Amukoye E; N Diaye A; Perronne C; Lienhardt C; McIlleron H; Fielding K
Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28438924
[TBL] [Abstract][Full Text] [Related]
33. Comparative safety of bedaquiline and delamanid in patients with multidrug resistant tuberculosis: A nationwide retrospective cohort study.
Kim JH; Lee H; Oh IS; Jeong HE; Bea S; Jang SH; Son H; Shin JY
J Microbiol Immunol Infect; 2023 Aug; 56(4):842-852. PubMed ID: 37202241
[TBL] [Abstract][Full Text] [Related]
34. Discovery and preclinical profile of sudapyridine (WX-081), a novel anti-tuberculosis agent.
Huang Z; Luo W; Xu D; Guo F; Yang M; Zhu Y; Shen L; Chen S; Tang D; Li L; Li Y; Wang B; Franzblau SG; Ding CZ
Bioorg Med Chem Lett; 2022 Sep; 71():128824. PubMed ID: 35636648
[TBL] [Abstract][Full Text] [Related]
35. Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study.
Ferlazzo G; Mohr E; Laxmeshwar C; Hewison C; Hughes J; Jonckheere S; Khachatryan N; De Avezedo V; Egazaryan L; Shroufi A; Kalon S; Cox H; Furin J; Isaakidis P
Lancet Infect Dis; 2018 May; 18(5):536-544. PubMed ID: 29452942
[TBL] [Abstract][Full Text] [Related]
36. Bedaquiline for the treatment of resistant tuberculosis: promises and pitfalls.
Kakkar AK; Dahiya N
Tuberculosis (Edinb); 2014 Jul; 94(4):357-62. PubMed ID: 24841672
[TBL] [Abstract][Full Text] [Related]
37. Population-level emergence of bedaquiline and clofazimine resistance-associated variants among patients with drug-resistant tuberculosis in southern Africa: a phenotypic and phylogenetic analysis.
Nimmo C; Millard J; van Dorp L; Brien K; Moodley S; Wolf A; Grant AD; Padayatchi N; Pym AS; Balloux F; O'Donnell M
Lancet Microbe; 2020 Aug; 1(4):e165-e174. PubMed ID: 32803174
[TBL] [Abstract][Full Text] [Related]
38. Bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis: a multicentre cohort study in Korea.
Kim CT; Kim TO; Shin HJ; Ko YC; Hun Choe Y; Kim HR; Kwon YS
Eur Respir J; 2018 Mar; 51(3):. PubMed ID: 29545276
[TBL] [Abstract][Full Text] [Related]
39. Improved outcomes following addition of bedaquiline and clofazimine to a treatment regimen for multidrug-resistant tuberculosis.
Yao G; Zhu M; Nie Q; Chen N; Tu S; Zhou Y; Xiao F; Liu Y; Li X; Chen H
J Int Med Res; 2023 Jan; 51(1):3000605221148416. PubMed ID: 36719280
[TBL] [Abstract][Full Text] [Related]
40. Sub-MIC levels of bedaquiline and clofazimine can select
Villellas C; Stevenaert F; Remmerie B; Andries K
Antimicrob Agents Chemother; 2024 Apr; 68(4):e0127523. PubMed ID: 38470194
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]